Apollomics Reports Full Year 2024 Financial Results and Highlights Clinical Updates and Business Progress

▤ Summary

Apollomics reported its full-year 2024 financial results and highlighted clinical progress for its oncology pipeline. The company announced a collaboration with LaunXP that brings a $10 million upfront payment and expands development of vebreltinib in combination with an EGFR inhibitor. Apollomics also shared interim data from its SPARTA trial across MET fusion, MET amplification, and MET exon 14 skipping patient groups. The company narrowed its strategic focus, cut expenses, and said current cash plus the LaunXP payment should fund operations into the first quarter of 2026.

▦ Linked Companies